- Invited speaker presentation
- Open Access
Integrated OMICS tools for personalised medicine
© Borro et al. 2015
- Published: 28 September 2015
- Personalise Medicine
- Methylation Profile
- Genetic Expression
- Personalise Therapy
- Personalise Healthcare
System-wide adoption of Personalised Healthcare requires an active and flexible but highly integrated infrastructure, joining many different competences and technologies and allowing continuous upgrading, also through self-learning processes. In this system, clinics and diagnostics would no longer be partitioned, according to a stepwise scheme, from other disciplines as basic science, information technologies, ethics and policies. Each player constitutes a node of a cabled network, where input and output from each node are automatically transferred to all nodes, to systematically retune and coordinate the global activity. Since 2005 the Sant'Andrea Hospital of Rome is an in-house built model of Personalised Healthcare Service, which auto-catalytically drives its own development, which may furnish good evidence that translation of Personalised Medicine into clinical practice is not so elusive. The interaction between usually distant academic departments and wards (as Biochemistry, Internal Medicine, Psychiatry, Oncology), favoured by a farsighted management of hospital resources by the administrators, allowed to create a shared, innovative laboratory, the Advanced Molecular Diagnostics Unit (DiMA). The availability of advanced technologies, as mass spectrometry and medium-to-high throughput DNA analysis paved the way to a “real-time” evaluation of the benefits brought into the “real-world” clinical practice by implementation of new diagnostics aimed to therapy tailoring. This allowed the start up of a health service based on the principles of personalised medicine, in order to optimize the amount of tests necessary to evaluate the patient, to interpret the results correctly and, finally, to plan a personalised therapy and to periodically evaluate and/or modify it, to obtain the best clinical results with the least side effects.
Our OMICS platform for personalised medicine offers the following combined approaches:
i) Epigenetics, to obtain information on the regulation of gene expression and to evaluate the methylation profile change during hypomethylation therapies;
ii) Functional genomics, to measure genetic expression in normal and pathologic conditions, in order to define genetic expression profiles;
iii) Structural genomics, which defines genomic differences with clinical impact in the patient populations;
iv) Metabolomics and terapeutic drug managment, to define all molecules of interest in a specific clinical context and the actual drug and metabolite concentration during therapies.
The MIFAR (Metabolismo Integrato FARmaci – drug metabolism integration) including about 60 gene variants has been developed. The data interpretation is ruled out using the Charité Bioinformatic platform (Berlin DE) and allows adaptation of drug therapies to the individual MIFAR profile, improving efficacy and safety of treatments. The DiMA Unit provides pharmacogenomics and theranostics report for at least 5,000 patients/year.
- Mariani S, Lionetto L, Cavallari M, Tubaro A, Rasio D, De Nunzio C, Hong GM, Borro M, Simmaco M: Low prostate concentration of lycopene is associated with development of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. Int J Mol Sci. 2014, 15 (1): 1433-40. 10.3390/ijms15011433. doi: 10.3390/ijms15011433PubMed CentralView ArticlePubMedGoogle Scholar
- Villa MP, Supino MC, Fedeli S, Rabasco J, Vitelli O, Del Pozzo M, Gentile G, Lionetto L, Barreto M, Simmaco M: Urinary concentration of 8-isoprostane as marker of severity of pediatric OSAS. Sleep Breath. 2014, 18 (4): 723-9. 10.1007/s11325-013-0934-0. doi: 10.1007/s11325-013-0934-0. Epub 2014 Jan 17View ArticlePubMedGoogle Scholar
- Negro A, Lionetto L, D'Alonzo L, Casolla B, Marsibilio F, Vignaroli G, Simmaco M, Martelletti P: Pharmacokinetic evaluation of almotriptan for the treatment of migraines. Expert Opin Drug Metab Toxicol. 2013, 9 (5): 637-44. 10.1517/17425255.2013.783012. doi: 10.1517/17425255.2013.783012. Epub 2013 Apr 9View ArticlePubMedGoogle Scholar
- Lionetto L, Casolla B, Cavallari M, Tisei P, Buttinelli C, Simmaco M: High-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification of carbamazepine, oxcarbazepine, and their main metabolites in human serum. Ther Drug Monit. 2012, 34 (1): 53-8. 10.1097/FTD.0b013e3182425168. doi: 10.1097/FTD.0b013e3182425168View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.